US20050015847A1 - Compositions and methods for preventing infection - Google Patents
Compositions and methods for preventing infection Download PDFInfo
- Publication number
- US20050015847A1 US20050015847A1 US10/637,793 US63779303A US2005015847A1 US 20050015847 A1 US20050015847 A1 US 20050015847A1 US 63779303 A US63779303 A US 63779303A US 2005015847 A1 US2005015847 A1 US 2005015847A1
- Authority
- US
- United States
- Prior art keywords
- virus
- composition
- cholesterol
- sequestering agent
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 238000000034 method Methods 0.000 title claims abstract description 51
- 208000015181 infectious disease Diseases 0.000 title abstract description 17
- 241000700605 Viruses Species 0.000 claims abstract description 92
- 239000003352 sequestering agent Substances 0.000 claims abstract description 76
- 230000007613 environmental effect Effects 0.000 claims abstract description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 31
- 230000005540 biological transmission Effects 0.000 claims description 20
- 230000002500 effect on skin Effects 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 16
- 239000001116 FEMA 4028 Substances 0.000 claims description 15
- 229960004853 betadex Drugs 0.000 claims description 15
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 14
- 230000002745 absorbent Effects 0.000 claims description 14
- 239000002250 absorbent Substances 0.000 claims description 14
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 239000010836 blood and blood product Substances 0.000 claims description 12
- 229940125691 blood product Drugs 0.000 claims description 12
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 230000003902 lesion Effects 0.000 claims description 8
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 241001529453 unidentified herpesvirus Species 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 230000014599 transmission of virus Effects 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 2
- 230000036576 dermal application Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 239000012528 membrane Substances 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 9
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 7
- 229940097362 cyclodextrins Drugs 0.000 description 6
- 238000000576 coating method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 206010067152 Oral herpes Diseases 0.000 description 3
- 241000710799 Rubella virus Species 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- 208000019802 Sexually transmitted disease Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- -1 e.g. Polymers 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000037262 Hepatitis delta Diseases 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- 241000701027 Human herpesvirus 6 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000726041 Human respirovirus 1 Species 0.000 description 2
- 241000712003 Human respirovirus 3 Species 0.000 description 2
- 241001559187 Human rubulavirus 2 Species 0.000 description 2
- 241001559186 Human rubulavirus 4 Species 0.000 description 2
- 241000700560 Molluscum contagiosum virus Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000005184 irreversible process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- CUJVBAPGYBSBHJ-YWBSARSQSA-N 2-[[(1R,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21R,23R,25R,26R,28R,30R,31R,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,38,40,42-tetrakis(carboxymethoxy)-10,15-bis(carboxymethoxymethyl)-37,39,41,43,44,45,46,47,48,49-decahydroxy-20,25,30,35-tetrakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]acetic acid Chemical compound OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](OCC(O)=O)[C@H]2O)[C@H](O)[C@H]5OCC(O)=O)[C@H](O)[C@H]4OCC(O)=O)[C@H](O)[C@H]3OCC(O)=O CUJVBAPGYBSBHJ-YWBSARSQSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 229930183931 Filipin Natural products 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- IMQSIXYSKPIGPD-NKYUYKLDSA-N filipin Chemical compound CCCCC[C@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-NKYUYKLDSA-N 0.000 description 1
- 229950000152 filipin Drugs 0.000 description 1
- IMQSIXYSKPIGPD-UHFFFAOYSA-N filipin III Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O IMQSIXYSKPIGPD-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 206010066435 human herpesvirus 8 infection Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007567 mass-production technique Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical class CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B42/00—Surgical gloves; Finger-stalls specially adapted for surgery; Devices for handling or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B42/00—Surgical gloves; Finger-stalls specially adapted for surgery; Devices for handling or treatment thereof
- A61B42/10—Surgical gloves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/10—Bandages or dressings; Absorbent pads specially adapted for fingers, hands, or arms; Finger-stalls; Nail-protectors
- A61F13/104—Bandages or dressings; Absorbent pads specially adapted for fingers, hands, or arms; Finger-stalls; Nail-protectors for the hands or fingers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00889—Material properties antimicrobial, disinfectant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00893—Material properties pharmaceutically effective
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00297—Wound bandages safety barrier for protection of the operator
- A61F2013/00302—Wound bandages safety barrier for protection of the operator devices for handling dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00297—Wound bandages safety barrier for protection of the operator
- A61F2013/00306—Wound bandages safety barrier for protection of the operator dressing for protection of the operator during surgical procedure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00297—Wound bandages safety barrier for protection of the operator
- A61F2013/0031—Wound bandages safety barrier for protection of the operator for handling common life objects, e.g. telephone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F2013/15008—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterized by the use
- A61F2013/15048—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterized by the use for protection against contamination, or protection in using body disinfecting wipes
- A61F2013/15065—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterized by the use for protection against contamination, or protection in using body disinfecting wipes for protecting in contaminated ambience, e.g. NBC or industrial chemicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F2013/15008—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterized by the use
- A61F2013/15081—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterized by the use as prophylaxis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- This invention relates to methods and compositions for preventing infection, and more particularly to methods and compositions using cholesterol-sequestering agents.
- HIV human immunodeficiency virus
- STDs sexually transmitted viral diseases
- non-sexually transmitted viral diseases such as influenza as well as infections caused by a variety of other microorganisms continue to flourish largely unchecked.
- HIV human immunodeficiency virus
- HSV herpes simplex virus
- STDs sexually transmitted diseases
- viricides that destroy non-sexually transmitted viruses causing diseases such as influenza and parainfluenza
- compounds that destroy wide spectrum of infectious microorganisms such as viruses, bacteria, mycobacteria, fungi, and protozoa.
- the invention features a composition containing an absorbent material containing a cholesterol-sequestering agent that prevents or reduces viral transmission, wherein the composition is formulated for dermal application to release an amount of the cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual when the composition is contacted to the skin of the individual.
- a “cholesterol-sequestering agent” refers to a compound that binds to cholesterol and extracts and depletes cholesterol from a biological membrane such as a plasma membrane or a membrane of an envelope virus.
- a cholesterol-sequestering agent preferentially extracts cholesterol from lipid rafts present in a biological membrane.
- the cholesterol-sequestering agent can be, for example, a cyclodextrin.
- the cholesterol-sequestering agent is a beta-cyclodextrin such as 2-OH-propyl-beta-cyclodextrin.
- the envelope virus can be, for example, a human immunodeficiency virus (HIV) such as HIV-1 or HIV-2; a human herpes virus (HHV) such as HHV1, HHV2, HHV3, HHV4, HHV5, HHV6, HHV7, or HHV8; a hepatitis virus such as hepatitis B virus, hepatitis C virus, or hepatitis D virus; a pox virus such as a small pox virus or molluscum contagiosum virus; an orthomyxovirus such as an influenza virus types A, B, or C; a paramyxovirus such as a mumps virus or a parainfluenza virus type 1, 2, 3, or 4; a human T-cell lymphotropic (HTLV) virus such as HTLV type I or II; a togaviruses such as rubella virus, yellow fever virus, or sinbis virus; ebola virus; or a coronavirus such as severe acute respiratory syndrome (
- compositions and methods described herein can be used to prevent dermal transmission of a variety of microorganisms, for example, a bacterium (e.g., anthrax or chlamydia), a mycobacterium (e.g., mycobacterium tuberculosis), a virus (e.g., a non-envelope virus, e.g., a protein coated virus such as picoma virus), a fungus, or a protozoan.
- a bacterium e.g., anthrax or chlamydia
- mycobacterium e.g., mycobacterium tuberculosis
- a virus e.g., a non-envelope virus, e.g., a protein coated virus such as picoma virus
- fungus e.g., a protozoan.
- the composition can be in any form that allows for the release of the cholesterol-sequestering agent to a surface of the skin.
- the cholesterol-sequestering agent can be contained in a swab or a towel such as a wipe.
- the absorbent material is cotton.
- the envelope virus is a human immunodeficiency virus (HIV).
- the envelope virus is a human herpes virus, a hepatitis virus, a pox virus, an influenza virus, a parainfluenza virus, or a human T-cell lymphotropic virus (HTLV).
- the invention also features a kit containing a plurality of compositions, e.g., swabs or wipes, described herein.
- a kit can contain at least 10, 50, 100, 500, 1,000, 10,000, or more of the compositions described herein.
- the compositions contained in the kits are sterilized.
- the invention features a glove containing an interior surface and an exterior surface, wherein the interior surface or the exterior surface of the glove is coated with an amount of a cholesterol-sequestering agent described herein effective to reduce or prevent dermal transmission of an envelope virus to an individual wearing the glove.
- the cholesterol-sequestering agent contained in the glove can be, for example, a cyclodextrin.
- the cholesterol-sequestering agent is a beta-cyclodextrin such as 2-OH-propyl-beta-cyclodextrin.
- the envelope virus can be any envelope virus described herein.
- the interior surface of the glove is coated with the cholesterol-sequestering agent.
- the exterior surface of the glove is coated with the cholesterol-sequestering agent.
- the interior surface and the exterior surface of the glove are coated with the cholesterol-sequestering agent.
- the interior and/or exterior of the glove can optionally be coated with a powder containing the cholesterol-sequestering agent.
- the envelope virus is a human immunodeficiency virus (HIV).
- the envelope virus is a human herpes virus, a hepatitis virus, a pox virus, an influenza virus, a parainfluenza virus, or a human T-cell lymphotropic virus (HTLV).
- the invention also features a kit containing a plurality of gloves containing a coating of a cholesterol-sequestering agent, as described herein.
- a kit can contain at least 10, 50, 100, 500, 1,000, 10,000, or more of the gloves described herein.
- the gloves contained in the kits are sterilized.
- the invention features a method of reducing or preventing viral transmission, the method including the steps of: selecting an individual engaged in an activity associated with an elevated risk of exposure to an envelope virus, wherein the activity is not a sexual or drug use-related activity; and contacting a skin surface of the individual with a composition containing an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of the envelope virus to the individual.
- the individual is a medical worker, e.g., a person that handles blood, blood products, or some other biological sample containing human material.
- the individual is a soldier.
- the method can be used to prevent the infection of a soldier with a pox virus.
- an extremity e.g., the hands
- the composition can be a glove containing an interior surface and an exterior surface, wherein the interior surface and/or the exterior surface of the glove is coated with an amount of the cholesterol-sequestering agent effective to reduce or prevent dermal transmission of the envelope virus to the individual.
- the composition contains an absorbent material containing the cholesterol-sequestering agent, wherein the composition is contacted to the skin surface of the individual and releases an amount of the cholesterol-sequestering agent effective to reduce or prevent transmission of the envelope virus to the individual.
- the composition is contacted to a portion of the skin containing a lesion or an irritation.
- the composition can be contacted to a portion of the skin containing a lesion resulting from a puncture of the skin with a medical instrument.
- the medical instrument is a needle or a scalpel.
- the composition contains a cream containing the cholesterol-sequestering agent. In another embodiment, the composition contains a spray containing the cholesterol-sequestering agent. In another embodiment, the composition contains a powder containing the cholesterol-sequestering agent.
- the invention features a method of treating an environmental surface, the method including the steps of: identifying a surface that has been exposed to blood or a blood product; and contacting the surface with a composition containing an amount of a cholesterol-sequestering agent effective to reduce the amount of an envelope virus, if present, on the surface.
- An environmental surface refers to a surface that is not made of living cells, e.g., a surface that does not contain the skin of an individual.
- An environmental surface includes, for example, tables, floors, chairs, equipment, instruments, and the like.
- the surface is located in a medical facility.
- the surface can be located in a patient care facility or in a medical laboratory.
- composition used according to the present method can be any composition described herein.
- the composition contains an absorbent material containing the cholesterol-sequestering agent, wherein the composition is contacted to the surface and releases an amount of the cholesterol-sequestering agent effective to reduce the amount of an envelope virus, if present, on the surface.
- the composition contains a spray containing the cholesterol-sequestering agent. In another embodiment, the composition contains a powder containing the cholesterol-sequestering agent.
- the present invention provides methods and compositions for preventing an infection by microorganisms such as envelope viruses.
- the methods and compositions of the invention make use of a cholesterol-sequestering agent that can have one or more of several possible effects on a microorganism.
- a cholesterol-sequestering agent may cause the lysis of the virus.
- a cholesterol-sequestering agent By removing cholesterol from a viral membrane, a cholesterol-sequestering agent not only disrupts the ordered structure of membrane elements, but further destroys the integrity of the membrane itself leading to disruption of the viral membrane and leakage of viral contents, an irreversible process that fully inactivates the viral particle.
- a cholesterol-sequestering agent may block the uptake of an intracellular pathogen by blocking endocytosis in a cell. Accordingly, a cholesterol-sequestering agent can be used to prevent dermal transmission of microorganisms and/or to decontaminate a surface that has come into contact with blood or a blood product that contains an envelope virus.
- a cholesterol-sequestering agent binds to cholesterol and extracts and depletes cholesterol from a biological membrane, such as a plasma membrane or a membrane of an envelope virus.
- a cholesterol-sequestering agent preferentially extracts cholesterol from lipid rafts present in a biological membrane.
- Examples of cholesterol-sequestering agents include compounds such as cyclodextrins, nystatin, and filipin.
- Cyclodextrins include both naturally occurring cyclodextrins, e.g., alpha, beta, and gamma cyclodextrins, as well as derivatives of naturally occurring cyclodextrins.
- Non-limiting examples of derivatives of naturally occurring cyclodextrins include derivatives of beta cyclodextrin such as hydroxypropyl beta cyclodextrin, carboxy-methyl beta cyclodextrin, and methyl beta cyclodextrin.
- Beta cyclodextrin a simple sugar ring structure containing seven alpha (1-4) glucopyranose units, has the ability to rapidly extract cholesterol from lipid rafts, thereby disrupting their ordered membrane structure. As a result of cholesterol removal, lipid rafts are dispersed in the plane of the membrane and the mechanisms responsible for entry and exit of envelop viruses from target cells are abolished.
- Beta cyclodextrin has a particularly high affinity for cholesterol. When used at concentrations ranging from 5-100 mM, 2-HP-BCD removes membrane cholesterol within minutes. At the molecular level, beta cyclodextrin resembles a toroid or cup-like structure with openings at both the top and bottom.
- the toroid structure contains hydrophilic groups on the exterior surface and hydrophobic groups on the interior surface. The hydrophylic groups confer solubility in aqueous medium while the hydrophobic groups form the hydrophobic pocket that binds the cholesterol.
- Hydroxypropyl beta cyclodextrin is an example of a derivative of beta cyclodextrin that can be used in the methods of the invention.
- Hydroxypropyl beta cyclodextrin is a partially substituted poly(hydroxpropyl) ether of beta cyclodextrin.
- the basic closed circular structure of beta cyclodextrin is maintained in hydroxypropyl beta cyclodextrin.
- the glycosidic oxygen forming the bond between the adjacent glucose monomers and the hydrogen atoms lining the cavity of the cyclodextrin impart an electron density and hydrophobic character to the cavity.
- Organic compounds interact with the walls of the cavity to form inclusion complexes.
- the hydroxyl groups and the hydroxypropyl groups are on the exterior of the molecule and interact with water to provide the increased aqueous solubility of the hydroxypropyl beta cyclodextrin and the complexes made with the hydroxypropyl beta cyclodextrin.
- hydroxypropyl beta cyclodextrin see, e.g., Muller et al. (1986) “Hydroxypropyl-B-cyclodextrin derivatives: Influence of average degree of substitution on complexing ability and surface activity” J. Pharm. Sci. 75.
- a cholesterol-sequestering agent not only disrupts the ordered structure of the membrane elements, but further destroys the integrity of the membrane itself leading to disruption of viral membranes and leakage of viral contents into the medium, an irreversible process that can fully inactivate the viral particle.
- Envelope viruses that can be targeted using the methods and compositions described herein include, but are not limited to: a human immunodeficiency virus (HIV) such as HIV-1 or HIV-2; a human herpes virus (HHV) such as HHV1, HHV2, HHV3, HHV4, HHV5, HHV6, HHV7, or HHV8; a hepatitis virus such as hepatitis B virus, hepatitis C virus, or hepatitis D virus; a pox virus such as a small pox virus or molluscum contagiosum virus; an orthomyxovirus such as an influenza virus types A, B, or C; a paramyxovirus such as a mumps virus or a parainfluenza virus type 1, 2, 3, or 4; a human T-cell lymphotropic virus (HTLV) such as HTLV type I or II; a togaviruses such as rubella virus, yellow fever virus, or sinbis virus; ebola
- the methods and compositions described herein can be used to prevent dermal transmission of a variety of microorganisms, for example, a bacterium (e.g., anthrax or chlamydia), a mycobacterium (e.g., mycobacterium tuberculosis), a virus (e.g., a non-envelope virus, e.g., a protein coated virus such as picoma virus), a fungus, or a protozoan.
- a bacterium e.g., anthrax or chlamydia
- mycobacterium e.g., mycobacterium tuberculosis
- a virus e.g., a non-envelope virus, e.g., a protein coated virus such as picoma virus
- fungus e.g., a protozoan.
- the methods and compositions described herein can be used to prevent clinical conditions that result from an infection by an envelope virus, including but not limited to AIDS (HIV infection), certain cancers (caused by HTLV types I and II), fever blisters or cold sores (Herpes labialis; HHV1 infection), genital herpes (Herpes genitalis; HHV2 infection), chicken pox (HHV3 infection), herpes zoster or shingles (HHV3 infection), mononucleosis (HHV4 infection), cytomegalovirus infection (HHV infection), Kaposi's Sarcoma (HHV8 infection), German measles (rubella virus infection), or severe acute respiratory syndrome (SARS virus infection).
- HIV infection HIV infection
- certain cancers caused by HTLV types I and II
- fever blisters or cold sores Herpes labialis
- HHV1 infection genital herpes
- HHV2 infection chicken pox
- HHV3 infection herpes z
- compositions can be formulated to contain an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual. Accordingly, the skin of an individual can be protected from viral transmission by applying a composition described herein to the skin.
- the cholesterol-sequestering agent can be contained in, for example, creams, lotions, ointments, gels, liquids, sprays, powders, or absorbent materials.
- the composition can be applied to the skin before and/or after contacting the skin with a material (e.g., blood or a blood product) that contains or potentially contains an infective envelope virus.
- Hands, other body extremities, and/or any exposed part of an individual can be contacted with the composition following the individual's exposure to blood or a blood product.
- the cholesterol-sequestering agent renders an envelope virus present on the individual's skin uninfective, thereby reducing the likelihood that the individual will become infected by the envelope virus.
- the methods encompass the application of the composition to both apparently healthy skin of the individual (e.g., skin lacking any observable lesions) as well as the application of the composition to an area of skin containing a lesion or an area of skin that is irritated and/or is a site of inflammation.
- the administration of the composition directly to the lesion can decrease the likelihood that the individual will become infected by the virus.
- compositions can be contacted with the skin in the form of, for example, a cream, lotion, gel, spray, or powder.
- the composition can be contained in an absorbent material, wherein the composition is formulated to release an amount of the cholesterol-sequestering agent effective to reduce or prevent dermal transmission of the envelope virus to the individual when the composition is contacted to the skin of the individual.
- an absorbent material examples include, but are not limited to, swabs or towels such as wipes. Such absorbent materials can be used to effectively clean an area of skin.
- Compositions used in such methods can contain additional antiviral and/or anti-microbial compounds in addition to the cholesterol-sequestering agent.
- hands and/or other portions of the body of an individual can also or in the alternative be contacted with the composition before exposure to blood or a blood product.
- Such preemptive action can be useful to provide an individual with protection in case an unexpected exposure to an envelope virus occurs, e.g., during the course of a medical procedure.
- the cholesterol-sequestering agent can be applied to the skin using any formulation, including but not limited to the various formulations described herein.
- an individual can also be protected against infection by an envelope virus by the use of a physical barrier that prevents the virus from contacting the skin.
- physical barriers frequently used in the medical community include gloves, gowns, masks, and eyewear. Any of these physical barriers can be formulated to also contain a cholesterol-sequestering agent described herein, so as to reduce or prevent the dermal transmission of an envelope virus that breaches such a physical barrier and reaches the skin of an individual.
- gloves can be used that contain a coating (an interior and/or exterior coating) of a composition containing a cholesterol-sequestering agent. Suitable gloves include any type that is used in medical and/or research environments.
- the gloves can be made of latex and can optionally be of the disposable variety.
- the coating of the composition can be in the form of a powder, cream, lotion, gel, or other suitable form.
- a composition containing a cholesterol-sequestering agent can also include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
- compositions described herein can also be used to treat an environmental surface, e.g., an inanimate surface in a medical or research facility.
- an environmental surface that has been exposed to blood or a blood product (or has been potentially exposed to blood or a blood product) is contacted with a composition containing an amount of a cholesterol-sequestering agent effective to reduce the amount of an envelope virus, if present, on the environmental surface.
- the cleaning of a surface with a composition described herein can be incorporated as part of a routine procedure carried out between separate uses of a given environmental surface.
- an environmental surface can be cleaned with a composition described herein during the interval between two patients or two sets of patient material being brought into contact with the same surface.
- the carrying out of the method decontaminates the environmental surface so as to reduce or eliminate the possibility that a patient or biological material that later contacts the surface will also come into contact with an envelope virus.
- compositions are described in the present application that contain an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual. These compositions are particularly useful for the inactivation of envelope viruses that contact the skin of an individual or that reside on a surface that has been contaminated by blood or a blood product.
- compositions can be prepared, e.g., by mass production techniques, to generate large numbers of substantially identical compositions, each of which may be subject to single or multiple use by an individual.
- gloves containing an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual wearing the glove can be prepared and packaged in containers, e.g., boxes, containing at least 10, 50, 100, 500, 1,000, 10,000, or more of such coated gloves.
- an absorbent composition e.g., a swab or a wipe
- a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual
- containers e.g., boxes, containing at least 10, 50, 100, 500, 1,000, 10,000, or more of such absorbent compositions.
- Instructions can be included with such containers (e.g., in the form of a paper included in the container or a writing on the container) that instruct the user that the composition reduces or prevents infection by an envelope virus described herein.
- Kits as described herein can also contain a dispenser that facilitates the removal of individual compositions from a container.
Abstract
Description
- This application claims priority from U.S. Provisional Application No. 60/402,318, filed Aug. 8, 2002. The prior application is incorporated herein by reference in its entirety.
- This invention relates to methods and compositions for preventing infection, and more particularly to methods and compositions using cholesterol-sequestering agents.
- Therapeutic approaches have proven largely ineffective for treating infections with envelope viruses such as human immunodeficiency virus (HIV) and other sexually transmitted viral diseases (STDs). In addition, non-sexually transmitted viral diseases such as influenza as well as infections caused by a variety of other microorganisms continue to flourish largely unchecked. The medical community is thus faced with a major need to develop: viricides that destroy human immunodeficiency virus (HIV), herpes simplex virus (HSV) and other causative agents of sexually transmitted diseases (STDs); viricides that destroy non-sexually transmitted viruses causing diseases such as influenza and parainfluenza; and compounds that destroy wide spectrum of infectious microorganisms, such as viruses, bacteria, mycobacteria, fungi, and protozoa.
- In one aspect, the invention features a composition containing an absorbent material containing a cholesterol-sequestering agent that prevents or reduces viral transmission, wherein the composition is formulated for dermal application to release an amount of the cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual when the composition is contacted to the skin of the individual.
- A “cholesterol-sequestering agent” refers to a compound that binds to cholesterol and extracts and depletes cholesterol from a biological membrane such as a plasma membrane or a membrane of an envelope virus. A cholesterol-sequestering agent preferentially extracts cholesterol from lipid rafts present in a biological membrane. The cholesterol-sequestering agent can be, for example, a cyclodextrin. In one example, the cholesterol-sequestering agent is a beta-cyclodextrin such as 2-OH-propyl-beta-cyclodextrin.
- The envelope virus can be, for example, a human immunodeficiency virus (HIV) such as HIV-1 or HIV-2; a human herpes virus (HHV) such as HHV1, HHV2, HHV3, HHV4, HHV5, HHV6, HHV7, or HHV8; a hepatitis virus such as hepatitis B virus, hepatitis C virus, or hepatitis D virus; a pox virus such as a small pox virus or molluscum contagiosum virus; an orthomyxovirus such as an influenza virus types A, B, or C; a paramyxovirus such as a mumps virus or a parainfluenza virus type 1, 2, 3, or 4; a human T-cell lymphotropic (HTLV) virus such as HTLV type I or II; a togaviruses such as rubella virus, yellow fever virus, or sinbis virus; ebola virus; or a coronavirus such as severe acute respiratory syndrome (SARS) virus. The envelope virus can be any type or any strain of a given envelope virus. Non-limiting examples of envelope viruses and various types are described herein.
- In addition to envelope viruses, the compositions and methods described herein can be used to prevent dermal transmission of a variety of microorganisms, for example, a bacterium (e.g., anthrax or chlamydia), a mycobacterium (e.g., mycobacterium tuberculosis), a virus (e.g., a non-envelope virus, e.g., a protein coated virus such as picoma virus), a fungus, or a protozoan.
- The composition can be in any form that allows for the release of the cholesterol-sequestering agent to a surface of the skin. For example, the cholesterol-sequestering agent can be contained in a swab or a towel such as a wipe. In one embodiment, the absorbent material is cotton.
- In one embodiment, the envelope virus is a human immunodeficiency virus (HIV). In other embodiments, the envelope virus is a human herpes virus, a hepatitis virus, a pox virus, an influenza virus, a parainfluenza virus, or a human T-cell lymphotropic virus (HTLV). The invention also features a kit containing a plurality of compositions, e.g., swabs or wipes, described herein. For example, a kit can contain at least 10, 50, 100, 500, 1,000, 10,000, or more of the compositions described herein. In some embodiments, the compositions contained in the kits are sterilized.
- In another aspect, the invention features a glove containing an interior surface and an exterior surface, wherein the interior surface or the exterior surface of the glove is coated with an amount of a cholesterol-sequestering agent described herein effective to reduce or prevent dermal transmission of an envelope virus to an individual wearing the glove.
- The cholesterol-sequestering agent contained in the glove can be, for example, a cyclodextrin. In one example, the cholesterol-sequestering agent is a beta-cyclodextrin such as 2-OH-propyl-beta-cyclodextrin. The envelope virus can be any envelope virus described herein. In one embodiment, the interior surface of the glove is coated with the cholesterol-sequestering agent. In another embodiment, the exterior surface of the glove is coated with the cholesterol-sequestering agent. In yet another embodiment, the interior surface and the exterior surface of the glove are coated with the cholesterol-sequestering agent. The interior and/or exterior of the glove can optionally be coated with a powder containing the cholesterol-sequestering agent.
- In one embodiment, the envelope virus is a human immunodeficiency virus (HIV). In other embodiments, the envelope virus is a human herpes virus, a hepatitis virus, a pox virus, an influenza virus, a parainfluenza virus, or a human T-cell lymphotropic virus (HTLV). The invention also features a kit containing a plurality of gloves containing a coating of a cholesterol-sequestering agent, as described herein. For example, a kit can contain at least 10, 50, 100, 500, 1,000, 10,000, or more of the gloves described herein. In some embodiments, the gloves contained in the kits are sterilized.
- In another aspect, the invention features a method of reducing or preventing viral transmission, the method including the steps of: selecting an individual engaged in an activity associated with an elevated risk of exposure to an envelope virus, wherein the activity is not a sexual or drug use-related activity; and contacting a skin surface of the individual with a composition containing an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of the envelope virus to the individual.
- In one embodiment, the individual is a medical worker, e.g., a person that handles blood, blood products, or some other biological sample containing human material. In another embodiment, the individual is a soldier. For example, the method can be used to prevent the infection of a soldier with a pox virus.
- In one embodiment, an extremity, e.g., the hands, of the individual is contacted with the composition. For example, the composition can be a glove containing an interior surface and an exterior surface, wherein the interior surface and/or the exterior surface of the glove is coated with an amount of the cholesterol-sequestering agent effective to reduce or prevent dermal transmission of the envelope virus to the individual. In another example, the composition contains an absorbent material containing the cholesterol-sequestering agent, wherein the composition is contacted to the skin surface of the individual and releases an amount of the cholesterol-sequestering agent effective to reduce or prevent transmission of the envelope virus to the individual.
- In one embodiment, the composition is contacted to a portion of the skin containing a lesion or an irritation. For example, the composition can be contacted to a portion of the skin containing a lesion resulting from a puncture of the skin with a medical instrument. In one embodiment, the medical instrument is a needle or a scalpel.
- In another embodiment, the composition contains a cream containing the cholesterol-sequestering agent. In another embodiment, the composition contains a spray containing the cholesterol-sequestering agent. In another embodiment, the composition contains a powder containing the cholesterol-sequestering agent.
- In another aspect, the invention features a method of treating an environmental surface, the method including the steps of: identifying a surface that has been exposed to blood or a blood product; and contacting the surface with a composition containing an amount of a cholesterol-sequestering agent effective to reduce the amount of an envelope virus, if present, on the surface. An environmental surface refers to a surface that is not made of living cells, e.g., a surface that does not contain the skin of an individual. An environmental surface includes, for example, tables, floors, chairs, equipment, instruments, and the like.
- In one embodiment, the surface is located in a medical facility. For example, the surface can be located in a patient care facility or in a medical laboratory.
- A composition used according to the present method can be any composition described herein. In one embodiment, the composition contains an absorbent material containing the cholesterol-sequestering agent, wherein the composition is contacted to the surface and releases an amount of the cholesterol-sequestering agent effective to reduce the amount of an envelope virus, if present, on the surface.
- In another embodiment, the composition contains a spray containing the cholesterol-sequestering agent. In another embodiment, the composition contains a powder containing the cholesterol-sequestering agent.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the exemplary methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present application, including definitions, will control. The materials, methods, and examples are illustrative only and not intended to be limiting.
- Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
- The present invention provides methods and compositions for preventing an infection by microorganisms such as envelope viruses. The methods and compositions of the invention make use of a cholesterol-sequestering agent that can have one or more of several possible effects on a microorganism. For some microorganisms such as envelope viruses, a cholesterol-sequestering agent may cause the lysis of the virus. By removing cholesterol from a viral membrane, a cholesterol-sequestering agent not only disrupts the ordered structure of membrane elements, but further destroys the integrity of the membrane itself leading to disruption of the viral membrane and leakage of viral contents, an irreversible process that fully inactivates the viral particle. In some instances, a cholesterol-sequestering agent may block the uptake of an intracellular pathogen by blocking endocytosis in a cell. Accordingly, a cholesterol-sequestering agent can be used to prevent dermal transmission of microorganisms and/or to decontaminate a surface that has come into contact with blood or a blood product that contains an envelope virus.
- Cholesterol-Sequestering Agent
- Any cholesterol-sequestering agent can be used in the methods and compositions of the invention. As described herein, a cholesterol-sequestering agent binds to cholesterol and extracts and depletes cholesterol from a biological membrane, such as a plasma membrane or a membrane of an envelope virus. A cholesterol-sequestering agent preferentially extracts cholesterol from lipid rafts present in a biological membrane.
- Examples of cholesterol-sequestering agents include compounds such as cyclodextrins, nystatin, and filipin. Cyclodextrins include both naturally occurring cyclodextrins, e.g., alpha, beta, and gamma cyclodextrins, as well as derivatives of naturally occurring cyclodextrins. Non-limiting examples of derivatives of naturally occurring cyclodextrins include derivatives of beta cyclodextrin such as hydroxypropyl beta cyclodextrin, carboxy-methyl beta cyclodextrin, and methyl beta cyclodextrin. For a detailed description on cyclodextrins and derivatives thereof, see, e.g., Parrish, M. A. “Cyclodextrins—a Review.” Sterling Organics Ltd., Newcastle-Upon-Tyne, England; and cyclodex.com.
- Beta cyclodextrin, a simple sugar ring structure containing seven alpha (1-4) glucopyranose units, has the ability to rapidly extract cholesterol from lipid rafts, thereby disrupting their ordered membrane structure. As a result of cholesterol removal, lipid rafts are dispersed in the plane of the membrane and the mechanisms responsible for entry and exit of envelop viruses from target cells are abolished.
- Beta cyclodextrin has a particularly high affinity for cholesterol. When used at concentrations ranging from 5-100 mM, 2-HP-BCD removes membrane cholesterol within minutes. At the molecular level, beta cyclodextrin resembles a toroid or cup-like structure with openings at both the top and bottom. The toroid structure contains hydrophilic groups on the exterior surface and hydrophobic groups on the interior surface. The hydrophylic groups confer solubility in aqueous medium while the hydrophobic groups form the hydrophobic pocket that binds the cholesterol.
- Hydroxypropyl beta cyclodextrin is an example of a derivative of beta cyclodextrin that can be used in the methods of the invention. Hydroxypropyl beta cyclodextrin is a partially substituted poly(hydroxpropyl) ether of beta cyclodextrin. The basic closed circular structure of beta cyclodextrin is maintained in hydroxypropyl beta cyclodextrin. The glycosidic oxygen forming the bond between the adjacent glucose monomers and the hydrogen atoms lining the cavity of the cyclodextrin impart an electron density and hydrophobic character to the cavity. Organic compounds interact with the walls of the cavity to form inclusion complexes. The hydroxyl groups and the hydroxypropyl groups are on the exterior of the molecule and interact with water to provide the increased aqueous solubility of the hydroxypropyl beta cyclodextrin and the complexes made with the hydroxypropyl beta cyclodextrin. For a detailed description of the structure of hydroxypropyl beta cyclodextrin, see, e.g., Muller et al. (1986) “Hydroxypropyl-B-cyclodextrin derivatives: Influence of average degree of substitution on complexing ability and surface activity” J. Pharm. Sci. 75.
- Compositions Containing Cholesterol-Sequestering Agents
- As detailed herein, by removing cholesterol from the membrane of an envelope virus, a cholesterol-sequestering agent not only disrupts the ordered structure of the membrane elements, but further destroys the integrity of the membrane itself leading to disruption of viral membranes and leakage of viral contents into the medium, an irreversible process that can fully inactivate the viral particle.
- Envelope viruses that can be targeted using the methods and compositions described herein include, but are not limited to: a human immunodeficiency virus (HIV) such as HIV-1 or HIV-2; a human herpes virus (HHV) such as HHV1, HHV2, HHV3, HHV4, HHV5, HHV6, HHV7, or HHV8; a hepatitis virus such as hepatitis B virus, hepatitis C virus, or hepatitis D virus; a pox virus such as a small pox virus or molluscum contagiosum virus; an orthomyxovirus such as an influenza virus types A, B, or C; a paramyxovirus such as a mumps virus or a parainfluenza virus type 1, 2, 3, or 4; a human T-cell lymphotropic virus (HTLV) such as HTLV type I or II; a togaviruses such as rubella virus, yellow fever virus, or sinbis virus; ebola virus; or a coronavirus such as severe acute respiratory syndrome (SARS) virus.
- In addition to envelope viruses, the methods and compositions described herein can be used to prevent dermal transmission of a variety of microorganisms, for example, a bacterium (e.g., anthrax or chlamydia), a mycobacterium (e.g., mycobacterium tuberculosis), a virus (e.g., a non-envelope virus, e.g., a protein coated virus such as picoma virus), a fungus, or a protozoan.
- The methods and compositions described herein can be used to prevent clinical conditions that result from an infection by an envelope virus, including but not limited to AIDS (HIV infection), certain cancers (caused by HTLV types I and II), fever blisters or cold sores (Herpes labialis; HHV1 infection), genital herpes (Herpes genitalis; HHV2 infection), chicken pox (HHV3 infection), herpes zoster or shingles (HHV3 infection), mononucleosis (HHV4 infection), cytomegalovirus infection (HHV infection), Kaposi's Sarcoma (HHV8 infection), German measles (rubella virus infection), or severe acute respiratory syndrome (SARS virus infection).
- A variety of compositions can be formulated to contain an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual. Accordingly, the skin of an individual can be protected from viral transmission by applying a composition described herein to the skin. The cholesterol-sequestering agent can be contained in, for example, creams, lotions, ointments, gels, liquids, sprays, powders, or absorbent materials. The composition can be applied to the skin before and/or after contacting the skin with a material (e.g., blood or a blood product) that contains or potentially contains an infective envelope virus.
- Hands, other body extremities, and/or any exposed part of an individual can be contacted with the composition following the individual's exposure to blood or a blood product. According to such a method, the cholesterol-sequestering agent renders an envelope virus present on the individual's skin uninfective, thereby reducing the likelihood that the individual will become infected by the envelope virus. The methods encompass the application of the composition to both apparently healthy skin of the individual (e.g., skin lacking any observable lesions) as well as the application of the composition to an area of skin containing a lesion or an area of skin that is irritated and/or is a site of inflammation. For a skin lesion resulting from a medical procedure carried out in the presence of blood or a blood products (e.g., a lesion resulting from a needle puncture or scalpel nick), the administration of the composition directly to the lesion can decrease the likelihood that the individual will become infected by the virus.
- The composition can be contacted with the skin in the form of, for example, a cream, lotion, gel, spray, or powder. In addition, the composition can be contained in an absorbent material, wherein the composition is formulated to release an amount of the cholesterol-sequestering agent effective to reduce or prevent dermal transmission of the envelope virus to the individual when the composition is contacted to the skin of the individual. Examples of compositions containing an absorbent material include, but are not limited to, swabs or towels such as wipes. Such absorbent materials can be used to effectively clean an area of skin. Compositions used in such methods can contain additional antiviral and/or anti-microbial compounds in addition to the cholesterol-sequestering agent.
- In addition to contacting skin with the composition following exposure to blood or a blood product, hands and/or other portions of the body of an individual can also or in the alternative be contacted with the composition before exposure to blood or a blood product. Such preemptive action can be useful to provide an individual with protection in case an unexpected exposure to an envelope virus occurs, e.g., during the course of a medical procedure. The cholesterol-sequestering agent can be applied to the skin using any formulation, including but not limited to the various formulations described herein.
- In addition to the compositions described herein, an individual can also be protected against infection by an envelope virus by the use of a physical barrier that prevents the virus from contacting the skin. Examples of physical barriers frequently used in the medical community include gloves, gowns, masks, and eyewear. Any of these physical barriers can be formulated to also contain a cholesterol-sequestering agent described herein, so as to reduce or prevent the dermal transmission of an envelope virus that breaches such a physical barrier and reaches the skin of an individual. For example, gloves can be used that contain a coating (an interior and/or exterior coating) of a composition containing a cholesterol-sequestering agent. Suitable gloves include any type that is used in medical and/or research environments. For example, the gloves can be made of latex and can optionally be of the disposable variety. The coating of the composition can be in the form of a powder, cream, lotion, gel, or other suitable form.
- A composition containing a cholesterol-sequestering agent can also include a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
- In addition to methods of contacting skin with a cholesterol-sequestering agent to reduce or prevent dermal transmission of an envelope virus, the compositions described herein can also be used to treat an environmental surface, e.g., an inanimate surface in a medical or research facility. In general an environmental surface that has been exposed to blood or a blood product (or has been potentially exposed to blood or a blood product) is contacted with a composition containing an amount of a cholesterol-sequestering agent effective to reduce the amount of an envelope virus, if present, on the environmental surface. The cleaning of a surface with a composition described herein can be incorporated as part of a routine procedure carried out between separate uses of a given environmental surface. For example, an environmental surface can be cleaned with a composition described herein during the interval between two patients or two sets of patient material being brought into contact with the same surface. The carrying out of the method decontaminates the environmental surface so as to reduce or eliminate the possibility that a patient or biological material that later contacts the surface will also come into contact with an envelope virus.
- Kits
- A variety of compositions are described in the present application that contain an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual. These compositions are particularly useful for the inactivation of envelope viruses that contact the skin of an individual or that reside on a surface that has been contaminated by blood or a blood product.
- The compositions can be prepared, e.g., by mass production techniques, to generate large numbers of substantially identical compositions, each of which may be subject to single or multiple use by an individual. For example, gloves containing an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual wearing the glove can be prepared and packaged in containers, e.g., boxes, containing at least 10, 50, 100, 500, 1,000, 10,000, or more of such coated gloves. In another example, an absorbent composition (e.g., a swab or a wipe) formulated to release an amount of a cholesterol-sequestering agent effective to reduce or prevent dermal transmission of an envelope virus to an individual can also be prepared and packaged in containers, e.g., boxes, containing at least 10, 50, 100, 500, 1,000, 10,000, or more of such absorbent compositions. Instructions can be included with such containers (e.g., in the form of a paper included in the container or a writing on the container) that instruct the user that the composition reduces or prevents infection by an envelope virus described herein.
- Kits as described herein can also contain a dispenser that facilitates the removal of individual compositions from a container.
- While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (45)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/637,793 US20050015847A1 (en) | 2002-08-08 | 2003-08-08 | Compositions and methods for preventing infection |
US12/407,733 US20090186056A1 (en) | 2002-08-08 | 2009-03-19 | Compositions and methods for preventing infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40231802P | 2002-08-08 | 2002-08-08 | |
US10/637,793 US20050015847A1 (en) | 2002-08-08 | 2003-08-08 | Compositions and methods for preventing infection |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/407,733 Continuation US20090186056A1 (en) | 2002-08-08 | 2009-03-19 | Compositions and methods for preventing infection |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050015847A1 true US20050015847A1 (en) | 2005-01-27 |
Family
ID=33415798
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/637,793 Abandoned US20050015847A1 (en) | 2002-08-08 | 2003-08-08 | Compositions and methods for preventing infection |
US12/407,733 Abandoned US20090186056A1 (en) | 2002-08-08 | 2009-03-19 | Compositions and methods for preventing infection |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/407,733 Abandoned US20090186056A1 (en) | 2002-08-08 | 2009-03-19 | Compositions and methods for preventing infection |
Country Status (3)
Country | Link |
---|---|
US (2) | US20050015847A1 (en) |
AU (1) | AU2003303948A1 (en) |
WO (1) | WO2004096121A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220294A1 (en) * | 2002-03-21 | 2003-11-27 | Wallace Kendall B. | Cyclodextrin compositions and methods of treating viral infections |
WO2007135523A2 (en) * | 2006-05-19 | 2007-11-29 | Viroblock S.A. | A composition for inactivating an enveloped virus |
US20090018072A1 (en) * | 2005-12-09 | 2009-01-15 | George Scheele | High protein supplement |
US8578519B2 (en) | 2010-12-03 | 2013-11-12 | Allen B. Kantrowitz | Surgical glove appliance device |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104287224A (en) * | 2014-08-06 | 2015-01-21 | 镇江苏惠乳胶制品有限公司 | Rubber glove with effect of preventing and treating pompholyx and manufacturing method thereof |
WO2023214204A1 (en) | 2022-05-05 | 2023-11-09 | Abdula Kurkayev | Pharmaceutical composition for restoring physiological processes and cells of organism |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352794A (en) * | 1979-11-27 | 1982-10-05 | Koch Juergen | Beta-cyclodextrin as anti-acne agent |
US5031245A (en) * | 1989-04-20 | 1991-07-16 | Smith & Nephew Plc | Gloves, their manufacture and use |
US5429628A (en) * | 1993-03-31 | 1995-07-04 | The Procter & Gamble Company | Articles containing small particle size cyclodextrin for odor control |
US5725875A (en) * | 1993-01-08 | 1998-03-10 | Microbarriers | Protective skin composition |
US6294186B1 (en) * | 1997-06-04 | 2001-09-25 | Peter William Beerse | Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
US20020128227A1 (en) * | 2000-03-08 | 2002-09-12 | Hildreth James E. | Beta-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
US20030220294A1 (en) * | 2002-03-21 | 2003-11-27 | Wallace Kendall B. | Cyclodextrin compositions and methods of treating viral infections |
US20040043041A1 (en) * | 1999-04-28 | 2004-03-04 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US20050148570A1 (en) * | 2001-11-08 | 2005-07-07 | Liren Huang | Novel substituted alkane compounds and uses thereof |
-
2003
- 2003-08-08 AU AU2003303948A patent/AU2003303948A1/en not_active Abandoned
- 2003-08-08 WO PCT/US2003/024704 patent/WO2004096121A2/en not_active Application Discontinuation
- 2003-08-08 US US10/637,793 patent/US20050015847A1/en not_active Abandoned
-
2009
- 2009-03-19 US US12/407,733 patent/US20090186056A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352794A (en) * | 1979-11-27 | 1982-10-05 | Koch Juergen | Beta-cyclodextrin as anti-acne agent |
US5031245A (en) * | 1989-04-20 | 1991-07-16 | Smith & Nephew Plc | Gloves, their manufacture and use |
US5031245B1 (en) * | 1989-04-20 | 1996-09-10 | Smith & Nephew | Gloves their manufacture and use |
US5725875A (en) * | 1993-01-08 | 1998-03-10 | Microbarriers | Protective skin composition |
US5429628A (en) * | 1993-03-31 | 1995-07-04 | The Procter & Gamble Company | Articles containing small particle size cyclodextrin for odor control |
US6294186B1 (en) * | 1997-06-04 | 2001-09-25 | Peter William Beerse | Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
US20040043041A1 (en) * | 1999-04-28 | 2004-03-04 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US20020128227A1 (en) * | 2000-03-08 | 2002-09-12 | Hildreth James E. | Beta-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
US6835717B2 (en) * | 2000-03-08 | 2004-12-28 | The Johns Hopkins University School Of Medicine | β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
US20050215522A1 (en) * | 2000-03-08 | 2005-09-29 | The Johns Hopkins University School Of Medicine | Beta-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
US7202231B2 (en) * | 2000-03-08 | 2007-04-10 | The Johns Hopkins University School Of Medicine | β-Cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
US20050148570A1 (en) * | 2001-11-08 | 2005-07-07 | Liren Huang | Novel substituted alkane compounds and uses thereof |
US20030220294A1 (en) * | 2002-03-21 | 2003-11-27 | Wallace Kendall B. | Cyclodextrin compositions and methods of treating viral infections |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070219159A1 (en) * | 2002-03-21 | 2007-09-20 | Regents Of The University Of Minnesota | Cyclodextrin compositions and methods of treating viral infections |
US20030220294A1 (en) * | 2002-03-21 | 2003-11-27 | Wallace Kendall B. | Cyclodextrin compositions and methods of treating viral infections |
US7982066B2 (en) | 2005-12-09 | 2011-07-19 | Novalife, Inc. | High protein supplement |
US8779189B2 (en) | 2005-12-09 | 2014-07-15 | George Scheele | High protein supplement |
US8362297B2 (en) | 2005-12-09 | 2013-01-29 | George Scheele | High protein supplement |
US20090018072A1 (en) * | 2005-12-09 | 2009-01-15 | George Scheele | High protein supplement |
AU2007252967B2 (en) * | 2006-05-19 | 2011-11-10 | Viroblock S.A. | A composition for inactivating an enveloped virus |
US20100137437A1 (en) * | 2006-05-19 | 2010-06-03 | Viroblock S.A. | Composition for Inactivating an Enveloped Virus |
JP2009537508A (en) * | 2006-05-19 | 2009-10-29 | ビロブロック エスアー | Composition for inactivating enveloped viruses |
EA016073B1 (en) * | 2006-05-19 | 2012-01-30 | Вайэроблок С.А. | A composition for inactivating an enveloped virus (variants), composition based thereon for preparing a medicament against virus disease, for preparing pharmaceutically amount of biocompatible disinfectant and for preparing coating agent comprising a kit for inactivating an enveloped virus and method therefor |
WO2007135523A3 (en) * | 2006-05-19 | 2008-06-26 | Viroblock S A | A composition for inactivating an enveloped virus |
KR101352165B1 (en) * | 2006-05-19 | 2014-01-15 | 바이로블럭 에스.에이. | A composition for inactivating an enveloped virus |
WO2007135523A2 (en) * | 2006-05-19 | 2007-11-29 | Viroblock S.A. | A composition for inactivating an enveloped virus |
US8889398B2 (en) | 2006-05-19 | 2014-11-18 | Viroblock Sa | Composition for inactivating an enveloped virus |
US20150065458A1 (en) * | 2006-05-19 | 2015-03-05 | Viroblock S.A. | Composition for Inactivating an Enveloped Virus |
US9526700B2 (en) * | 2006-05-19 | 2016-12-27 | Viroblock Sa | Composition for inactivating an enveloped virus |
US8578519B2 (en) | 2010-12-03 | 2013-11-12 | Allen B. Kantrowitz | Surgical glove appliance device |
Also Published As
Publication number | Publication date |
---|---|
US20090186056A1 (en) | 2009-07-23 |
WO2004096121A2 (en) | 2004-11-11 |
AU2003303948A8 (en) | 2004-11-23 |
WO2004096121A3 (en) | 2007-01-04 |
AU2003303948A1 (en) | 2004-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8853272B2 (en) | Method for treating an inflammation or lesion caused by a virus | |
US20090186056A1 (en) | Compositions and methods for preventing infection | |
RU2657532C2 (en) | Physical method of combating microorganisms | |
US7192607B2 (en) | Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations into mucosal cavities | |
CA2188319C (en) | Coated products with potent anti-hiv and antimicrobial properties | |
JP2006519841A (en) | Surface disinfecting composition with improved antibacterial performance | |
AU744623B2 (en) | Broad spectrum microbicidal and spermicidal compositions, devices, and methods | |
US20090324643A1 (en) | Compositions and methods for treating and preventing infection | |
EP1372389B1 (en) | Virucidal compositions | |
US20070173481A1 (en) | Compositions and methods for preventing infection | |
AU2002251933A1 (en) | Virucidal compositions | |
WO1993018745A1 (en) | Use of antiviral coating for latex items such as condoms | |
AU783242B2 (en) | Methods and devices for preventing transmission of sexually transmitted diseases | |
RU2204385C2 (en) | 2,4-dichlorobenzyl alcohol and amylmethacresol against hiv-infection | |
CN116528844A (en) | Methods and compositions for inhibiting enveloped viruses using high molecular weight hydrophobically modified polymers | |
CN115916169A (en) | Methods and compositions for inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers | |
Digenis et al. | Coated-Products with Potent Anti-HIV and Antimicrobial Properties | |
NZ527295A (en) | Applicator for delivering a liquid or semi-solid topical formulation into a mucosal cavity, for example, a vagina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE JOHNS HOPKINS UNIVERSITY, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HILDRETH, JAMES E.;REEL/FRAME:016683/0102 Effective date: 20051014 |
|
AS | Assignment |
Owner name: LA JOLLA BIOSCIENCES LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHEELE, GEORGE A.;REEL/FRAME:016948/0626 Effective date: 20051224 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA Free format text: CONFIRMATORY LICENSE;ASSIGNOR:THE JOHNS HOPKINS UNIVERSITY;REEL/FRAME:048683/0533 Effective date: 20190312 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:JOHNS HOPKINS UNIVERSITY;REEL/FRAME:058136/0833 Effective date: 20190306 |